Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Blueprint Medicines
Blueprint Medicines
Roche, Blueprint raise pressure on Lilly with new Gavreto approval
Pharmaforum
Wed, 12/2/20 - 10:33 am
Roche
Blueprint Medicines
Gavreto
thyroid cancer
Retevmo
Eli Lilly
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Endpoints
Tue, 09/22/20 - 10:17 pm
Blueprint Medicines
Roche
FDA
Ayvakit
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Sun, 09/6/20 - 07:22 pm
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib
Pharmaceutical Business Review
Tue, 07/14/20 - 10:29 am
Roche
Blueprint Medicines
pralsetinib
RET-altered cancer
FDA approval tracker: several early decisions in May
EP Vantage
Wed, 06/3/20 - 10:24 am
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Fierce Pharma
Mon, 05/18/20 - 10:59 pm
Blueprint Medicines
Deciphera
FDA
GIST
Ayvakit
Qinlock
After a PhIII failure, the FDA delivers Blueprint an expected CRL
Endpoints
Fri, 05/15/20 - 10:37 am
Blueprint Medicines
FDA
complete response letter
Ayvakit
gastrointestinal stromal tumors
A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind
Endpoints
Sun, 05/10/20 - 09:30 pm
Eli Lilly
selpercatinib
Retevmo
FDA
cancer
Loxo Oncology
Blueprint Medicines
Blueprint’s voyage ends in disaster
EP Vantage
Wed, 04/29/20 - 10:45 am
Blueprint Medicines
Ayvakit
clinical trials
The crucial data readouts coming soon for small biotechs
EP Vantage
Thu, 04/23/20 - 12:37 pm
clinical trials
Akebia
Blueprint Medicines
Genfit
TG Therapeutics
vadadustat
Ayvakit
elafibranor
Blueprint hits goal in midphase rare disease trial, teeing up pivotal study
Fierce Biotech
Mon, 03/16/20 - 11:52 pm
Blueprint Medicines
avapritinib
clinical trials
systemic mastocytosis
Go or no go? Esperion's double whammy and a look to priority reviews
EP Vantage
Thu, 01/30/20 - 10:43 am
FDA
Esperion Therapeutics
Acacia Pharma
Blueprint Medicines
Agile Therapeutics
Lundbeck
Sun Pharma
Biohaven
Durect Corporation
Racing Blueprint, Lilly drug gets priority review for RET hopeful
Fierce Biotech
Wed, 01/29/20 - 10:35 am
Eli Lilly
FDA
Blueprint Medicines
selpercatinib
LOXO-292
thyroid cancer
non-small cell lung cancer
Blueprint gets first approval as FDA backs stomach cancer drug
Pharmaforum
Fri, 01/10/20 - 10:20 am
Blueprint Medicines
FDA
Ayvakit
stomach cancer
Ipsen doubles down on rare bone disease
EP Vantage
Wed, 10/16/19 - 07:18 pm
Ipsen
FOP
BLU-782
Blueprint Medicines
Clementia Pharmaceuticals
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
Mon, 09/9/19 - 08:08 pm
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
Sun, 06/9/19 - 01:36 pm
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
Wed, 06/5/19 - 10:43 am
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Mon, 06/3/19 - 11:25 am
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292
Blueprint posts 'impressive' data for lead candidate, but investor response tepid
Biopharma Dive
Fri, 11/16/18 - 08:06 pm
Blueprint Medicines
clinical trials
avapritinib
gastrointestinal cancer
Pages
« first
‹ previous
1
2
3
next ›
last »